Emalex Biosciences is a biopharmaceutical company focused on developing treatments for neurological disorders, particularly pediatric Tourette syndrome
Emalex Biosciences is a biopharmaceutical company focused on developing treatments for neurological disorders, particularly pediatric Tourette syndrome. Its lead candidate, ecopipam, is a first-in-class selective dopamine D1 receptor antagonist.